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Nonhemolytic passenger lymphocyte 
syndrome: donor-derived anti-M in an M+ 
recipient of a multiorgan transplant
A.T. Makuria, A. Langeberg, T.M. Fishbein, and S.G. Sandler
Passenger lymphocyte syndrome (PLS) is a well-recognized com-
plication that may follow a hematopoietic progenitor cell or 
solid-organ transplant. Typically, the syndrome presents as acute 
hemolysis of the recipient’s RBCs, which have become serological-
ly incompatible with blood group antibodies formed by passively 
transfused donor-origin B lymphocytes. Most cases involve anti-A 
or anti-B. However, there are cases involving non-ABO serologic 
incompatibility, as well as cases in which the serologic incompat-
ibility was not associated with clinical evidence of hemolysis. This 
report describes a case of passenger lymphocyte syndrome in an 
M+ recipient who developed anti-M after receiving a multiorgan 
transplant from an M– cadaver donor. Although the temporal 
events and serologic findings were consistent with a diagnosis of 
PLS, there was no evidence of in vivo hemolysis associated with 
the identification of a newly formed anti-M. This report includes a 
literature review of other case reports of PLS associated with non-
ABO antibodies in solid-organ and hematopoietic progenitor cell 
transplant recipients. Immunohematology 2009:25:20–23.
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Patients undergoing hematopoietic stem cell or solid-organ transplants may develop hemolytic reactions if viable B lymphocytes are passively transfused with 
the transplant and form antibodies to blood group antigens 
expressed on the recipient’s RBCs (passenger lymphocyte 
syndrome, PLS). Ideally, all transplant candidates would 
be matched with ABO-identical donors. However, because 
of the shortage of ABO-matched donors and because genes 
encoding human leukocyte antigens (HLAs) and control-
ling A and B blood group antigens segregate separately, 
ABO matching is often compromised to achieve an optimal 
HLA donor-recipient match.1
PLS was first observed in recipients of ABO-mismatched 
(nonidentical) bone marrow transplants in whom hemolysis 
was caused by anti-A or anti-B of donor origin.2,3 The syn-
drome continues to be observed involving anti-A or anti-B,4 
but is recognized increasingly to be a potential complica-
tion of mismatched antigens of other blood group systems, 
as well as in recipients of solid-organ transplants.5
We report the first case, to our knowledge, of PLS 
caused by anti-M in an M+ recipient of a solid-organ or 
a hematopoietic stem cell transplant. Our patient did not 
exhibit clinical signs of hemolysis. The absence of clinical 
evidence of hemolysis in our patient is consistent with the 
usual clinical outcome for serologic incompatibility involv-
ing anti-M in the presence of M+ RBCs. 
Case Report
A 44-year-old man with idiopathic small bowel motil-
ity disorder experienced severe liver failure associated with 
total parenteral nutrition therapy. His past history included 
a colon resection and correction of pseudo-obstruction, but 
no blood transfusions. He underwent a successful multi-
organ transplant including stomach, small intestine, large 
intestine, pancreas, and liver from a cadaver donor and 
was discharged 6 weeks later. Immediate posttransplanta-
tion treatment consisted of tacrolimus (Prograf, Astellas 
Pharma US, Dearfield, IL) 3 mg/day, adjusted to maintain 
a blood level of 18 to 20 ng/mL; sirolimus (Rapamune, Wy-
eth Pharmaceuticals, Philadelphia, PA); 4 mg/day, adjusted 
to maintain a blood level of 5 to 10 ng/mL; and methylpred-
nisolone (Solu-Medrol, Pfizer, NY, NY),  500 mg/day, and 
tapered. 
The transplant recipient’s blood type was group A, D+. 
No blood group antibodies were detected in his plasma by 
a highly sensitive solid-phase antibody screen (ABS2000, 
Immucor, Norcross, GA) before transplantation. The organ 
donor’s blood type was group A, D+. During the peritrans-
plant period, the transplant recipient was transfused with 
5 units of frozen plasma and 9 units of gamma-irradiated 
RBCs (leukocyte-reduced).
The patient did not require blood transfusions until 
posttransplant day 16, when the transfusion service per-
formed the first posttransplant antibody screen (Table 1).On 
that day, the recipient’s indirect and direct antiglobulin test 
results were positive for the first time. Anti-M was detected 
in his plasma by an automated solid-phase antibody screen 
(Capture-R Ready-Screen 4, Immucor/Gamma, Norcross, 
GA; score = 3/7) and by a standard manual tube identifi-
cation panel (Panocell-10, Immucor; Table 1). Anti-M was 
identified on his circulating RBCs by rapid acid elution 
(Gamma Elu-Kit II, Immucor). The serologic characteristics 
were consistent with a naturally occurring anti-M, i.e., an 
antibody that reacted selectively with M+ RBCs by immedi-
ate spin at room temperature, but not if the patient’s plas-
ma and reagent RBCs were prewarmed to 37°C.6 Because 
alloimmunization to transfused M+ RBCs would occur only 
in an M–, not an M+, recipient, we considered the possibil-
ity of PLS caused by anti-M of donor origin. The diagnosis 
of PLS was confirmed when a sample of the organ donor’s 
RBCs, which was obtained through the organ retrieval ser-
vice, was typed as M–. The organ donor’s hospital reported 
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a negative antibody screen on admission, but the method 
used (ProVue, Ortho Diagnostics, Raritan, NJ) rarely detects 
antibodies reacting at room temperature, which, typically, 
are not clinically significant for routine blood transfu-
sions.7,8 A sample of the organ donor’s pretransplantation 
plasma was not available for a repeat antibody screen, this 
time at room temperature, as is required for detecting most 
examples of anti-M. The transplant recipient’s positive di-
rect antiglobulin test result persisted until posttransplant 
day 45. During the entire posttransplantation period, there 
was no clinical evidence of hemolysis.
Discussion
PLS is a well-described immune hemolytic syndrome 
after solid-organ, as well as hematopoietic progenitor cell, 
transplantation. It has been observed after transplantation 
of kidney, lung, heart-lung, liver, pancreas, and pancreas-
spleen,1,9–20 as well as hematopoietic progenitor cell (HPC) 
transplantation.1–4,21–27 In our case, the patient received a 
cadaver stomach, small intestine, large intestine, pancreas, 
and liver. In this newly described technique, the patient’s 
duodenum and pancreas were retained, but because of 
the need to replace his stomach, the donor’s pancreas and 
intestine were also transplanted en-bloc.28 PLS, typically 
characterized by acute hemolysis caused by blood group 
antibody(s), occurs when donor-origin B lymphocytes are 
passively transferred with the transplant and subsequently 
form antibodies to the blood group antigens on the recipi-
ent’s RBCs.
Although most cases of PLS involve the ABO blood group 
system, PLS has been associated with serologic incompat-
ibilities in other blood group systems. Table 2 summarizes 
a literature review of other reports of PLS involving non-
ABO blood group antigens in hematopoietic progenitor cell 
and solid-organ transplants. We were unable to find a prior 
report of PLS involving anti-M in a solid-organ transplant 
recipient. PLS, which may be regarded as a variant of graft-
versus-host disease (GVHD),19,29 rarely occurs after blood 
transfusions today, because hospital transfusion services 
routinely exclude blood components from donors known 
to have alloantibodies and gamma irradiate blood compo-
nents for transplant recipients to prevent transfusion 
associated GVHD.
The immune response in PLS may be primary or sec-
ondary (anamnestic). Hemolysis may be acute or delayed, 
or as in our case, there may be serologic incompatibility 
without hemolysis.25 The time of onset of hemolysis var-
ies from days to weeks, but is most often observed between 
days 5 and 15 after hematopoietic progenitor cell or solid-
organ transplants.
In our patient, detection of anti-M in an M+ transplant 
recipient was the specific event that raised the possibil-
ity of PLS. The diagnosis was confirmed by demonstrating 
that the recipient’s RBC phenotype was M+, whereas the 
donor’s RBC phenotype was M–. An alternative interpre-
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Table 2. Literature review of passenger lymphocyte syndrome involving 





Kidney (2) Anti-D 9
Kidney (1) Anti-D 10
Kidney (1) Anti-D 11
Kidney (1) Anti-D 12
Kidney (1) Anti-D 13
Kidney (1) Anti-c 14
Liver (1) Anti-D, -C, -k 4
Liver (1) Anti-D 15
Liver (1) Anti-D 16
Liver (1) Anti-Jka 17
Liver (1) Anti-K, -Fya 18
Pancreas (1) Anti-D 19
Lungs (2) Anti-D 4
Heart-lung (1) Anti-D 20
Kidney and pancreas (1) Anti-Fya 18
Bone marrow (1) Anti-Lea 21
Bone marrow (1) Anti-D 22
Bone marrow (1) Anti-D 23
Bone marrow (2) Anti-D 3
Bone marrow (1) Anti-D, -C, -E 3
PBPC (1) Anti-Jka 24
PBPC (1) Anti-Jka 25
PBPC (2) Anti-Jka 26
PBPC (1) Anti-Jka, -E, -Dib 27
n = number of cases
PBPC = peripheral blood progenitor cell











Anti-IgG + C3d 
(prewarmed)
-1 0 NT NT NT M+ or M- RBCs: 
0(NT)
+16 1+w 1+w 0 1+ M+ RBCs: 1+ (0)
M- RBCs: 0 (NT)
+21 1+ 1+ 0 1+ M+ RBCs: 1+ (0)
M- RBCs: 0 (NT)
+29 1+ 1+ 0 1+ M+ RBCs: 1+ (0)
M- RBCs: 0 (NT)
+45 0 0 0 1+s M+ RBCs: 0 (NT)
M- RBCs: 0 (NT)
NT = not tested; RT = room temperature.
Days after 
transplant Direct antiglobulin test
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tation, although less likely given the temporal and clini-
cal events, is that the M+ transplant recipient developed 
auto-anti-M, coincidentally, during the narrow window 
when one would anticipate onset of PLS. Case reports of 
these uncommon examples of auto-anti-M have been sum-
marized by Issitt and Anstee.30 Many transfusion services 
have adopted serologic methods to avoid routine detection 
of room temperature, saline-reactive (only) “naturally oc-
curring” alloantibodies, because they are considered to be 
clinically insignificant.6–8,31 In our case, anti-M was detect-
ed as a new antibody during a routine posttransplantation 
antibody screen. The antibody was detected using a highly 
sensitive solid-phase assay for routine antibody screens and 
a room temperature, saline immediate spin reading for the 
crossmatch. Anti-M in our patient was not associated with 
clinical evidence of hemolysis of his M+ RBCs.  Absence of 
clinical evidence of hemolysis is the typical clinical finding 
for most, but not all, examples of anti-M when present in 
the plasma of patients who may be transfused with allogeneic 
M+ RBCs 
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